APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastroparesis Drugs

Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.

Selected research

Market Outlook & Growth Opportunities

Global Gastroparesis Drugs Market Outlook and Growth Opportunities 2026

28 December 2025194 pages

Choose your research edition.

Industry ResearchGastroparesis Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastroparesis Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Gastroparesis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastroparesis Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastroparesis Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.

North America is the largest consumer of Gastroparesis Drugs in global market.The second place is Europe, following North America.

Market is not concentrated. Sumitomo, Cadila Pharmaceuticals, Sanofi, Teva and Johnson & Johnsonare the leaders of the industry, and hold the key technologies and patent, with high-end customers.

Read the full market overview

This report provides an overview of the global Gastroparesis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastroparesis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastroparesis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastroparesis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Gastroparesis Drugs Segment by Company

Sumitomo

Cadila Pharmaceuticals

Sanofi

Teva

Johnson & Johnson

Pfizer

Kyowa Kirin Pharmaceuticals

Hanmi Pharm

Ani Pharmaceuticals

Gastroparesis Drugs Segment by Type

Prokinetic Agents

Antiemetic Agents

Others

Gastroparesis Drugs Segment by Application

Diabetic Gastroparesis

Idiopathic Gastroparesis

Gastroparesis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gastroparesis Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gastroparesis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gastroparesis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Gastroparesis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastroparesis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastroparesis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastroparesis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gastroparesis Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastroparesis Drugs industry.

Chapter 3: Detailed analysis of Gastroparesis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gastroparesis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gastroparesis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gastroparesis Drugs Industry Trends Table 2. Gastroparesis Drugs Industry Drivers Table 3. Gastroparesis Drugs Industry Opportunities and Challenges Table 4. Gastroparesis Drugs Industry Restraints Table 5. Global Gastroparesis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gastroparesis Drugs Revenue Share by Company (2021-2026) Table 7. Global Gastroparesis Drugs Sales Volume by Company (Kg) & (2021-2026) Table 8. Global Gastroparesis Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Gastroparesis Drugs Average Price (US$/mg) of Company (2021-2026) Table 10. Global Gastroparesis Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gastroparesis Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Gastroparesis Drugs Company, Product Type & Application Table 13. Global Gastroparesis Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gastroparesis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Prokinetic Agents Table 18. Significant Companies of Antiemetic Agents Table 19. Significant Companies of Others Table 20. Global Gastroparesis Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Kg) Table 21. Global Gastroparesis Drugs Sales Volume by Type (2021-2026) & (Kg) Table 22. Global Gastroparesis Drugs Sales Volume by Type (2027-2032) & (Kg) Table 23. Global Gastroparesis Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Gastroparesis Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Gastroparesis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Gastroparesis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Gastroparesis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Gastroparesis Drugs Sales Value Share by Type (2021-2026) Table 29. Global Gastroparesis Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Diabetic Gastroparesis Table 31. Significant Companies of Idiopathic Gastroparesis Table 32. Global Gastroparesis Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Kg) Table 33. Global Gastroparesis Drugs Sales Volume by Application (2021-2026) & (Kg) Table 34. Global Gastroparesis Drugs Sales Volume by Application (2027-2032) & (Kg) Table 35. Global Gastroparesis Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Gastroparesis Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Gastroparesis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Gastroparesis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Gastroparesis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Gastroparesis Drugs Sales Value Share by Application (2021-2026) Table 41. Global Gastroparesis Drugs Sales Value Share by Application (2027-2032) Table 42. Global Gastroparesis Drugs Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 43. Global Gastroparesis Drugs Sales by Region (2021-2026) & (Kg) Table 44. Global Gastroparesis Drugs Sales Market Share by Region (2021-2026) Table 45. Global Gastroparesis Drugs Sales by Region (2027-2032) & (Kg) Table 46. Global Gastroparesis Drugs Sales Market Share by Region (2027-2032) Table 47. Global Gastroparesis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Gastroparesis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Gastroparesis Drugs Sales Value Share by Region (2021-2026) Table 50. Global Gastroparesis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Gastroparesis Drugs Sales Value Share by Region (2027-2032) Table 52. Global Gastroparesis Drugs Market Average Price (US$/mg) by Region (2021-2026) Table 53. Global Gastroparesis Drugs Market Average Price (US$/mg) by Region (2027-2032) Table 54. Global Gastroparesis Drugs Sales by Country: 2021 VS 2025 VS 2032 (Kg) Table 55. Global Gastroparesis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Gastroparesis Drugs Sales by Country (2021-2026) & (Kg) Table 57. Global Gastroparesis Drugs Sales Market Share by Country (2021-2026) Table 58. Global Gastroparesis Drugs Sales by Country (2027-2032) & (Kg) Table 59. Global Gastroparesis Drugs Sales Market Share by Country (2027-2032) Table 60. Global Gastroparesis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Gastroparesis Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Gastroparesis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Gastroparesis Drugs Sales Value Market Share by Country (2027-2032) Table 64. Sumitomo Company Information Table 65. Sumitomo Business Overview Table 66. Sumitomo Gastroparesis Drugs Sales (Kg), Value (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 67. Sumitomo Gastroparesis Drugs Product Portfolio Table 68. Sumitomo Recent Development Table 69. Cadila Pharmaceuticals Company Information Table 70. Cadila Pharmaceuticals Business Overview Table 71. Cadila Pharmaceuticals Gastroparesis Drugs Sales (Kg), Value (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 72. Cadila Pharmaceuticals Gastroparesis Drugs Product Portfolio Table 73. Cadila Pharmaceuticals Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Gastroparesis Drugs Sales (Kg), Value (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 77. Sanofi Gastroparesis Drugs Product Portfolio Table 78. Sanofi Recent Development Table 79. Teva Company Information Table 80. Teva Business Overview Table 81. Teva Gastroparesis Drugs Sales (Kg), Value (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 82. Teva Gastroparesis Drugs Product Portfolio Table 83. Teva Recent Development Table 84. Johnson & Johnson Company Information Table 85. Johnson & Johnson Business Overview Table 86. Johnson & Johnson Gastroparesis Drugs Sales (Kg), Value (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 87. Johnson & Johnson Gastroparesis Drugs Product Portfolio Table 88. Johnson & Johnson Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Gastroparesis Drugs Sales (Kg), Value (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 92. Pfizer Gastroparesis Drugs Product Portfolio Table 93. Pfizer Recent Development Table 94. Kyowa Kirin Pharmaceuticals Company Information Table 95. Kyowa Kirin Pharmaceuticals Business Overview Table 96. Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Sales (Kg), Value (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 97. Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Product Portfolio Table 98. Kyowa Kirin Pharmaceuticals Recent Development Table 99. Hanmi Pharm Company Information Table 100. Hanmi Pharm Business Overview Table 101. Hanmi Pharm Gastroparesis Drugs Sales (Kg), Value (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 102. Hanmi Pharm Gastroparesis Drugs Product Portfolio Table 103. Hanmi Pharm Recent Development Table 104. Ani Pharmaceuticals Company Information Table 105. Ani Pharmaceuticals Business Overview Table 106. Ani Pharmaceuticals Gastroparesis Drugs Sales (Kg), Value (US$ Million), Price (US$/mg) and Gross Margin (2021-2026) Table 107. Ani Pharmaceuticals Gastroparesis Drugs Product Portfolio Table 108. Ani Pharmaceuticals Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Gastroparesis Drugs Distributors List Table 112. Gastroparesis Drugs Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Gastroparesis Drugs Product Image Figure 2. Global Gastroparesis Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastroparesis Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gastroparesis Drugs Sales (2021-2032) & (Kg) Figure 5. Global Gastroparesis Drugs Sales Average Price (US$/mg) & (2021-2032) Figure 6. Global Gastroparesis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Prokinetic Agents Image Figure 10. Antiemetic Agents Image Figure 11. Others Image Figure 12. Global Gastroparesis Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Kg) Figure 13. Global Gastroparesis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Gastroparesis Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Gastroparesis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Gastroparesis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Gastroparesis Drugs Sales Value Share by Type (2021-2032) Figure 18. Diabetic Gastroparesis Image Figure 19. Idiopathic Gastroparesis Image Figure 20. Global Gastroparesis Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Kg) Figure 21. Global Gastroparesis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Gastroparesis Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Gastroparesis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Gastroparesis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Gastroparesis Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Gastroparesis Drugs Sales by Region: 2021 VS 2025 VS 2032 (Kg) Figure 27. Global Gastroparesis Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Gastroparesis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Gastroparesis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Gastroparesis Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Gastroparesis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Gastroparesis Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Gastroparesis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Gastroparesis Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Gastroparesis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Gastroparesis Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Gastroparesis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Gastroparesis Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Gastroparesis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Gastroparesis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Gastroparesis Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Gastroparesis Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Prokinetic Agents
  • Antiemetic Agents
  • Others
Applications
  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
Companies covered
  • Sumitomo
  • Cadila Pharmaceuticals
  • Sanofi
  • Teva
  • Johnson & Johnson
  • Pfizer
  • Kyowa Kirin Pharmaceuticals
  • Hanmi Pharm
  • Ani Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gastroparesis Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Gastroparesis Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Gastroparesis Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gastroparesis Drugs Market Dynamics
  1. 2.1 Gastroparesis Drugs Industry Trends
  2. 2.2 Gastroparesis Drugs Industry Drivers
  3. 2.3 Gastroparesis Drugs Industry Opportunities and Challenges
  4. 2.4 Gastroparesis Drugs Industry Restraints
3 Gastroparesis Drugs Market by Company
  1. 3.1 Global Gastroparesis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Gastroparesis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Gastroparesis Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Gastroparesis Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Gastroparesis Drugs Company Ranking (2024-2026)
  6. 3.6 Global Gastroparesis Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Gastroparesis Drugs Company Product Type and Application
  8. 3.8 Global Gastroparesis Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gastroparesis Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gastroparesis Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gastroparesis Drugs Market by Type
  1. 4.1 Gastroparesis Drugs Type Introduction
  2. 4.1.1 Prokinetic Agents
  3. 4.1.2 Antiemetic Agents
  4. 4.1.3 Others
  5. 4.2 Global Gastroparesis Drugs Sales Volume by Type
  6. 4.2.1 Global Gastroparesis Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Gastroparesis Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Gastroparesis Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Gastroparesis Drugs Sales Value by Type
  10. 4.3.1 Global Gastroparesis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Gastroparesis Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Gastroparesis Drugs Sales Value Share by Type (2021-2032)
5 Gastroparesis Drugs Market by Application
  1. 5.1 Gastroparesis Drugs Application Introduction
  2. 5.1.1 Diabetic Gastroparesis
  3. 5.1.2 Idiopathic Gastroparesis
  4. 5.2 Global Gastroparesis Drugs Sales Volume by Application
  5. 5.2.1 Global Gastroparesis Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Gastroparesis Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Gastroparesis Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Gastroparesis Drugs Sales Value by Application
  9. 5.3.1 Global Gastroparesis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Gastroparesis Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Gastroparesis Drugs Sales Value Share by Application (2021-2032)
6 Gastroparesis Drugs Regional Sales and Value Analysis
  1. 6.1 Global Gastroparesis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastroparesis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Gastroparesis Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Gastroparesis Drugs Sales by Region (2027-2032)
  5. 6.3 Global Gastroparesis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gastroparesis Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gastroparesis Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gastroparesis Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Gastroparesis Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gastroparesis Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Gastroparesis Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gastroparesis Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Gastroparesis Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gastroparesis Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gastroparesis Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gastroparesis Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Gastroparesis Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gastroparesis Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gastroparesis Drugs Sales Value Share by Country, 2025 VS 2032
7 Gastroparesis Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Gastroparesis Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gastroparesis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gastroparesis Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Gastroparesis Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Gastroparesis Drugs Sales by Country (2027-2032)
  6. 7.4 Global Gastroparesis Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gastroparesis Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gastroparesis Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gastroparesis Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gastroparesis Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gastroparesis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sumitomo
  2. 8.1.1 Sumitomo Company Information
  3. 8.1.2 Sumitomo Business Overview
  4. 8.1.3 Sumitomo Gastroparesis Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sumitomo Gastroparesis Drugs Product Portfolio
  6. 8.1.5 Sumitomo Recent Developments
  7. 8.2 Cadila Pharmaceuticals
  8. 8.2.1 Cadila Pharmaceuticals Company Information
  9. 8.2.2 Cadila Pharmaceuticals Business Overview
  10. 8.2.3 Cadila Pharmaceuticals Gastroparesis Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Cadila Pharmaceuticals Gastroparesis Drugs Product Portfolio
  12. 8.2.5 Cadila Pharmaceuticals Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Gastroparesis Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Gastroparesis Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Teva
  20. 8.4.1 Teva Company Information
  21. 8.4.2 Teva Business Overview
  22. 8.4.3 Teva Gastroparesis Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Teva Gastroparesis Drugs Product Portfolio
  24. 8.4.5 Teva Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Gastroparesis Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Gastroparesis Drugs Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Gastroparesis Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Gastroparesis Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Kyowa Kirin Pharmaceuticals
  38. 8.7.1 Kyowa Kirin Pharmaceuticals Company Information
  39. 8.7.2 Kyowa Kirin Pharmaceuticals Business Overview
  40. 8.7.3 Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Product Portfolio
  42. 8.7.5 Kyowa Kirin Pharmaceuticals Recent Developments
  43. 8.8 Hanmi Pharm
  44. 8.8.1 Hanmi Pharm Company Information
  45. 8.8.2 Hanmi Pharm Business Overview
  46. 8.8.3 Hanmi Pharm Gastroparesis Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hanmi Pharm Gastroparesis Drugs Product Portfolio
  48. 8.8.5 Hanmi Pharm Recent Developments
  49. 8.9 Ani Pharmaceuticals
  50. 8.9.1 Ani Pharmaceuticals Company Information
  51. 8.9.2 Ani Pharmaceuticals Business Overview
  52. 8.9.3 Ani Pharmaceuticals Gastroparesis Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ani Pharmaceuticals Gastroparesis Drugs Product Portfolio
  54. 8.9.5 Ani Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gastroparesis Drugs Value Chain Analysis
  2. 9.1.1 Gastroparesis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gastroparesis Drugs Sales Mode & Process
  6. 9.2 Gastroparesis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gastroparesis Drugs Distributors
  9. 9.2.3 Gastroparesis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst